Conditioned market authorization in China on February 5, 2021
l The results of pre-clinical and clinical research trials were published in Science and The Lancet.
l The Phase Ⅲ and real-world studies conducted in some other countries showed that CoronaVac® is safe for adults at all ages ≥ 18. It also showed a significant effect on reducing the incidence, hospitalization and death rate caused by COVID-19 infection.
lThe inactivated COVID-19 Vaccine, CoronaVac®, was recommended under WHO Emergency Use Listing (EUL).
l The annual production capacity is over 2 billion doses, and the vaccine has been approved to use by more than 40 countries around the world.